ESC 2019 - Implantable cardioverter-defibrillator associated with lower mortality in heart failure
Implantable cardioverter-defibrillator ( ICD ) use is associated with reduced short- and long-term mortality in patients with heart failure.
Patients with heart failure are at increased risk of potentially lethal ventricular arrhythmias and sudden cardiac death.
ICDs are used to correct these arrhythmias and prevent sudden death.
ESC guidelines recommend an ICD for primary prevention in symptomatic patients with heart failure with reduced ejection fraction ( HFrEF ), provided they are expected to survive substantially longer than one year with good functional status.
Most randomised trials on ICD use for primary prevention of sudden cardiac death in HFrEF enrolled patients more than 20 years ago.
However, characteristics and management of HFrEF have substantially changed since then and it is not known whether ICD improves outcome on top of contemporary treatments.
Furthermore, it is unclear whether ICD use is equally beneficial in subgroups such as both women and men or older and younger patients.
The study has investigated the association between ICD use and all-cause mortality in a contemporary HFrEF cohort with a focus on subgroups.
The study population was compiled from patients in the Swedish Heart Failure Registry ( SwedeHF ) fulfilling ESC criteria for primary prevention ICD use.
Propensity score matching was used to account for differences at baseline.
Of 16,702 eligible patients in SwedeHF, 1,599 ( 9.6% ) had an ICD.
Among patients from SwedeHF fulfilling ESC criteria for primary prevention ICD use, less than 10% had the device.
ICD use in Sweden is known to be lower than in other European countries ( e.g. Germany or Italy ). This could be because most heart failure patients are seen by primary care physicians and geriatricians who could be less inclined to accept device therapy and have a higher perception of contraindications compared to cardiologists.
The propensity matched population consisted of 1,296 ICD users and 1,296 patients without an ICD.
The researchers found that ICD use was associated with a 26% relative reduction in the risk of all-cause mortality at one year and a 13% relative reduction in the risk of all-cause mortality at five years.
The five-year absolute risk reduction with ICD use was 3.1% leading to 33 patients needing to be treated to prevent one death in five years.
The short-term and long-term mortality benefit was consistent across subgroups, such as patients with or without ischaemic heart disease, males and females, patients under 75 and 75 and older, those enrolled earlier versus later in SwedeHF and thus receiving less or more contemporary treatment, and also for patients with or without cardiac resynchronisation therapy.
In conclusion, the study found that primary prevention ICD was associated with reduced short-term and long-term all-cause mortality in HFrEF overall and in several subgroups.
The findings support the current recommendations and call for better implementation of ICD use in clinical practice.
The study was published in Circulation. ( Xagena )
Source: European Society of Cardiology ( ESC ) Congress 2019
The FDA ( U.S. Food and Drug Administration ) has approved Darzalex Faspro ( Daratumumab and Hyaluronidase-fihj ), a...
The Pfizer-BioNTech COVID-19 vaccine contains a nucleoside-modified messenger RNA ( modRNA ) encoding the viral spike glycoprotein ( S ) of...
COVID-19 can have fatal consequences for people with underlying cardiovascular disease and cause cardiac injury even in patients without underlying...
Atrial fibrillation is the most frequent sustained arrhythmia. Atrial fibrillation often recurs after restoration of normal sinus rhythm. Antiarrhythmic drugs...
Brukinsa for the treatment of patients with relapsed and refractory mantle cell lymphoma, FDA approved
The FDA ( U.S. Food and Drug Administration ) has granted accelerated approval to Brukinsa ( Zanubrutinib ) capsules for...
The European Commission has approved a label update for the use of once-daily Relvar Ellipta ( Fluticasone furoate / Vilanterol,...
Hyperkalemia at admission is associated with in-hospital mortality and hypokalemia with cardiac arrest and new-onset atrial fibrillation in patients admitted with suspected acute coronary syndrome
In acute coronary syndrome ( ACS ), potassium imbalance at admission has been associated with in-hospital arrhythmias, cardiac arrest, and...
Anthracycline-induced cardiotoxicity was first reported in early 1970s. Since then, there has been increasing recognition of its association with poor...
As the Zika virus continues to spread globally, new evidence has emerged about the virus's potentially detrimental effects on the...